Clarivate Plc (NYSE: CLVT) reported financial results for the third quarter ended September 30, 2026, highlighting the completion of a major strategic divestiture. On October 6, 2026, the company closed the sale of its Life Sciences & Healthcare (LS&H) segment for net cash proceeds of $488.4 million. Following this transaction, LS&H is now classified as discontinued operations.
Total revenues for the third quarter of 2026 were $567.9 million, a decrease of $55.2 million (8.9%) compared to the same period in 2025. This decline was primarily driven by inorganic disposals. Excluding the LS&H segment, continuing operations generated $481.6 million in revenue, down 9.2% year-over-year.
Organic revenue growth for continuing operations increased by 0.4% in the third quarter. Subscription revenues increased 0.7% to $338.3 million, while organic subscription growth reached 1.5%. Recurring revenues, which consist of subscription and re-occurring revenues, grew 1.3% organically. Adjusted net income for the third quarter was $136.0 million, or $0.21 per diluted share, compared to $119.3 million, or $0.18 per diluted share, in the prior year.
For the first nine months of 2026, total revenues were $1.7407 billion, compared to $1.8382 billion in the prior year. Adjusted net income for the nine-month period was $378.4 million, or $0.59 per diluted share. The company generated $399.0 million of operating cash flow and $233.1 million of free cash flow during the first nine months of 2026.
Clarivate provided updated financial outlooks for the full year and fourth quarter of 2026, excluding discontinued operations. The company expects full-year 2026 revenues between $1.965 billion and $1.985 billion, with Adjusted EBITDA projected between $865 million and $885 million. For the fourth quarter alone, revenue is expected to be between $490 million and $510 million.
